According to study authors, “Our findings highlight the importance of considering indirect costs alongside efficacy, safety, and direct costs during the treatment decision-making process.”
Patients recently diagnosed with multiple myeloma are incurring greater healthcare costs compared with patients diagnosed just a few years earlier, however, those additional dollars spent coincide with substantial gains in survival, according to a recent study.
The current time to diagnose multiple myeloma is higher than most other cancers and could be significantly reduced, according to a recent study published in BMJ Open.
Research presented at the ASH 2017 Annual Meeting & Exposition highlighted how costs for autologous stem cell transplantation have decreased over the past decade.
In one survey of payers, 47.6% reported having pathways for multiple myeloma, with another 19.1% citing the cancer type as a high priority for pathway development, Edmund Pezalla, MD, MPH, chief executive officer of Enlightenment BioConsult, explained at the AMCP Annual Meeting 2017.